Safety Evaluation of Intracoronary Infusion of Extracellular Vesicles in Patients Following Coronary Stent Implantation

Inclusion Criteria: * Undergoing ≥1 elective, urgent, or emergent coronary stent implantation * Angiographic evidence of TIMI 3 flow through the stented vessel after stent placement * Angiographic evidence of residual stenosis visually \<30% after stent placement * Willing and able to provide signed informed consent * Lives within 90 mile radius of study site * Willing and able to return to study site for all follow-up visits Exclusion Criteria: * Prior solid organ transplantation at any time * Pregnant or lactating at screening * Known presence of chronic systemic inflammatory disorder that requires ongoing therapy with immunosuppressive agents * Known immune system compromise including but not limited to human immunodeficiency virus (HIV), hepatitis A, hepatitis B (HBV) or hepatitis C (HCV) infection * Known history of malignancy of any type except non-melanoma skin cancer * Known serum creatinine \>2 mg/dL or GFR ≤30 mL/min within the last twelve months * Known AST, ALT, and/or bilirubin (total) elevated twice the upper limit of normal for age \& gender within the last twelve months * Known Hemoglobin lower than 8.0 g/dL within the last twelve months * Known current illicit drug use at screening * Other major surgical procedure or major trauma within the previous 14 days prior to enrollment * Female of child bearing potential who is unwilling to agree to use acceptable contraception methods for 3 months after receiving the investigational drug * Pacemaker/ICD implant in place * Adult lacking decision-making capacity * Prisoner * Non-English speaking * English-speaking but illiterate * Legally blind * Known allergy to heparin or heparin-induced thrombocytopenia * Known history of positive SARS-CoV2 testing within the last 30 days * DNR/DNI status prior to PCI procedure or planned DNR/DNI status after PCI procedure * Homeless or no permanent address at the time of enrollment